Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals
Increlex is indicated for the treatment of growth failure in certain pediatric patients.
Financial terms were not disclosed.
Under the terms of the deal, Esteve will license non-US Increlex rights for up to 10 years and will receive an option to acquire the international rights in the future, the company said, adding it will supply the product to Esteve at a fixed transfer price.
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
ISS recommends votes against Bank of America's CEO pay
Reuters - 25 minutes ago
-
MT Newswires - 27 minutes ago
-
Trump administration to hold oil, gas lease sale in Gulf of Mexico
Reuters - 29 minutes ago
-
Microsoft, turning 50, dials up Copilot actions to stay in AI game
Reuters - 31 minutes ago
-
Kroger Insider Sold Shares Worth $392,258, According to a Recent SEC Filing
MT Newswires - 31 minutes ago
-
Microsoft, turning 50, dials up Copilot actions to stay in AI game
Reuters - 33 minutes ago
-
FS Bancorp Approves Expanded Stock Buyback
MT Newswires - 44 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
